USA — In a groundbreaking development, the Food and Drug Administration (FDA) has granted approval for a gene therapy treatment to address severe hemophilia A, an uncommon and potentially life-threatening blood disorder.
The newly approved drug, named Roctavian and developed by BioMarin Pharmaceutical, has the potential to spare individuals with the severe form of the disease from a lifetime of frequent injections.
Upon its initial approval, it is estimated that approximately 2,500 out of the 6,500 Americans affected by severe hemophilia A will be eligible to receive this transformative treatment.
Roctavian employs a single infusion method to introduce the missing genes in individuals with hemophilia A, potentially providing effective results for years to come.
This latest approval marks a significant milestone in gene therapy, leading the way toward a future where thousands of diseases can be treated using similar techniques.
The FDA has previously authorized gene therapies for various conditions, including sickle cell anemia and spinal muscular atrophy.
However, the utilization of gene therapies remains relatively limited due to their high costs, with Roctavian priced at US$2.9 million for a single infusion and Hemgenix, a treatment for another form of hemophilia, costing US$3.5 million per use.
Gene therapy encompasses a wide range of medical interventions that utilize genetic material to treat diseases.
These therapies rely on specialized carriers, such as inert viruses and lipid spheres, to deliver healthy genes to the targeted areas.
Hemophilia A is caused by a genetic mutation that disrupts blood clotting, putting individuals at risk of uncontrollable bleeding, even during routine activities.
Roctavian, administered intravenously, introduces neutralized viruses to the liver, enabling the insertion of the gene responsible for producing a blood-clotting protein.
In the realm of genetic medicine, a distinction is often made between gene therapy, which introduces healthy genetic material, and gene editing, which involves modifying existing genes.
While the FDA has approved therapies falling into the former category, gene editing therapies have not yet received regulatory authorization.
Since the FDA’s initial approval of a gene therapy treatment in 2017 for a specific form of leukemia known as Kymriah, the agency has continued to authorize over 30 cellular- and gene-based therapies, including Roctavian.
The surge in proposals for new gene therapies has presented challenges for the FDA’s evaluation process, as the agency receives hundreds of requests each year.
However, this growing field holds immense potential for the future of medicine. As researchers explore the effects of gene therapy and gene editing, their applications may extend beyond rare disorders.
These techniques show promise for addressing conditions such as cancer, high cholesterol, and unhealthy weight in the years to come.
Ethical considerations and future outlook
While gene therapy and genetic research offer remarkable possibilities, they also raise ethical concerns similar to those surrounding stem cell biology and cloning.
Bioethicists are particularly cautious about heritable genetic modifications passed down from parent to child.
Current federal law prohibits the intentional creation or modification of a human embryo to include heritable genetic changes.
As scientists continue to evaluate the efficacy and safety of gene therapies, they are hopeful that these techniques will revolutionize disease management, providing viable alternatives for patients who lack effective treatment options.
Looking ahead, the FDA is poised to assess the first gene editing treatments utilizing Vertex Pharmaceutical’s CRISPR tool.
These therapies, which aim to treat sickle cell disease and beta-thalassemia, are expected to undergo FDA review by March 2024, potentially opening new frontiers in genetic medicine.
For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.
